Selected research
Industry Research
Microbiome CDMO Industry Research Report 2026
Market perspective
The global Microbiome CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Microbiome CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Microbiome CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Microbiome CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Microbiome CDMO include Arranta Bio, Wacker Chemie AG, Bactera, SGS Quay Pharma, Biose, EnteroBiotix, Genome And Company, Lallemand Health Solutions and List Bio, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Microbiome CDMO market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Microbiome CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Microbiome CDMO Market by Company
Arranta Bio
Wacker Chemie AG
Bactera
SGS Quay Pharma
Biose
EnteroBiotix
Genome And Company
Lallemand Health Solutions
List Bio
Rise BioServices
Lonza
MaaT Pharma
NIZO
Quay Pharmaceuticals
Recipharm
Microbiome CDMO Segment by Type
Microbial CDMO
Antibiotic CDMO
Phage CDMO
Bacteriocins CDMO
Microbiome CDMO Segment by Application
Vaccine R&D
Biopharmaceutical
Cell Therapy
Others
Microbiome CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Microbiome CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Microbial CDMO
- Antibiotic CDMO
- Phage CDMO
- Bacteriocins CDMO
Applications
- Vaccine R&D
- Biopharmaceutical
- Cell Therapy
- Others
Companies covered
- Arranta Bio
- Wacker Chemie AG
- Bactera
- SGS Quay Pharma
- Biose
- EnteroBiotix
- Genome And Company
- Lallemand Health Solutions
- List Bio
- Rise BioServices
- Lonza
- MaaT Pharma
- NIZO
- Quay Pharmaceuticals
- Recipharm
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Microbiome CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Microbial CDMO
- 2.2.3 Antibiotic CDMO
- 2.2.4 Phage CDMO
- 2.2.5 Bacteriocins CDMO
- 2.3 Microbiome CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Vaccine R&D
- 2.3.3 Biopharmaceutical
- 2.3.4 Cell Therapy
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Microbiome CDMO Breakdown Data by Type
- 3.1 Global Microbiome CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Microbiome CDMO Forecasted Market Size by Type (2027-2032)
4 Microbiome CDMO Breakdown Data by Application
- 4.1 Global Microbiome CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Microbiome CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Microbiome CDMO Market Perspective (2021-2032)
- 5.2 Global Microbiome CDMO Growth Trends by Region
- 5.2.1 Global Microbiome CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Microbiome CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Microbiome CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Microbiome CDMO Market Dynamics
- 5.3.1 Microbiome CDMO Industry Trends
- 5.3.2 Microbiome CDMO Market Drivers
- 5.3.3 Microbiome CDMO Market Challenges
- 5.3.4 Microbiome CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Microbiome CDMO Players by Revenue
- 6.1.1 Global Top Microbiome CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Microbiome CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Microbiome CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Microbiome CDMO Head Office and Area Served
- 6.4 Global Microbiome CDMO Players, Product Type & Application
- 6.5 Global Microbiome CDMO Manufacturers Established Date
- 6.6 Global Microbiome CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Microbiome CDMO Market Size (2021-2032)
- 7.2 North America Microbiome CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Microbiome CDMO Market Size by Country (2021-2026)
- 7.4 North America Microbiome CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Microbiome CDMO Market Size (2021-2032)
- 8.2 Europe Microbiome CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Microbiome CDMO Market Size by Country (2021-2026)
- 8.4 Europe Microbiome CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Microbiome CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Microbiome CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Microbiome CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Microbiome CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Microbiome CDMO Market Size (2021-2032)
- 10.2 South America Microbiome CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Microbiome CDMO Market Size by Country (2021-2026)
- 10.4 South America Microbiome CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Microbiome CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Microbiome CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Microbiome CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Microbiome CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Arranta Bio
- 12.1.1 Arranta Bio Company Information
- 12.1.2 Arranta Bio Business Overview
- 12.1.3 Arranta Bio Revenue in Microbiome CDMO Business (2021-2026)
- 12.1.4 Arranta Bio Microbiome CDMO Product Portfolio
- 12.1.5 Arranta Bio Recent Developments
- 12.2 Wacker Chemie AG
- 12.2.1 Wacker Chemie AG Company Information
- 12.2.2 Wacker Chemie AG Business Overview
- 12.2.3 Wacker Chemie AG Revenue in Microbiome CDMO Business (2021-2026)
- 12.2.4 Wacker Chemie AG Microbiome CDMO Product Portfolio
- 12.2.5 Wacker Chemie AG Recent Developments
- 12.3 Bactera
- 12.3.1 Bactera Company Information
- 12.3.2 Bactera Business Overview
- 12.3.3 Bactera Revenue in Microbiome CDMO Business (2021-2026)
- 12.3.4 Bactera Microbiome CDMO Product Portfolio
- 12.3.5 Bactera Recent Developments
- 12.4 SGS Quay Pharma
- 12.4.1 SGS Quay Pharma Company Information
- 12.4.2 SGS Quay Pharma Business Overview
- 12.4.3 SGS Quay Pharma Revenue in Microbiome CDMO Business (2021-2026)
- 12.4.4 SGS Quay Pharma Microbiome CDMO Product Portfolio
- 12.4.5 SGS Quay Pharma Recent Developments
- 12.5 Biose
- 12.5.1 Biose Company Information
- 12.5.2 Biose Business Overview
- 12.5.3 Biose Revenue in Microbiome CDMO Business (2021-2026)
- 12.5.4 Biose Microbiome CDMO Product Portfolio
- 12.5.5 Biose Recent Developments
- 12.6 EnteroBiotix
- 12.6.1 EnteroBiotix Company Information
- 12.6.2 EnteroBiotix Business Overview
- 12.6.3 EnteroBiotix Revenue in Microbiome CDMO Business (2021-2026)
- 12.6.4 EnteroBiotix Microbiome CDMO Product Portfolio
- 12.6.5 EnteroBiotix Recent Developments
- 12.7 Genome And Company
- 12.7.1 Genome And Company Company Information
- 12.7.2 Genome And Company Business Overview
- 12.7.3 Genome And Company Revenue in Microbiome CDMO Business (2021-2026)
- 12.7.4 Genome And Company Microbiome CDMO Product Portfolio
- 12.7.5 Genome And Company Recent Developments
- 12.8 Lallemand Health Solutions
- 12.8.1 Lallemand Health Solutions Company Information
- 12.8.2 Lallemand Health Solutions Business Overview
- 12.8.3 Lallemand Health Solutions Revenue in Microbiome CDMO Business (2021-2026)
- 12.8.4 Lallemand Health Solutions Microbiome CDMO Product Portfolio
- 12.8.5 Lallemand Health Solutions Recent Developments
- 12.9 List Bio
- 12.9.1 List Bio Company Information
- 12.9.2 List Bio Business Overview
- 12.9.3 List Bio Revenue in Microbiome CDMO Business (2021-2026)
- 12.9.4 List Bio Microbiome CDMO Product Portfolio
- 12.9.5 List Bio Recent Developments
- 12.10 Rise BioServices
- 12.10.1 Rise BioServices Company Information
- 12.10.2 Rise BioServices Business Overview
- 12.10.3 Rise BioServices Revenue in Microbiome CDMO Business (2021-2026)
- 12.10.4 Rise BioServices Microbiome CDMO Product Portfolio
- 12.10.5 Rise BioServices Recent Developments
- 12.11 Lonza
- 12.11.1 Lonza Company Information
- 12.11.2 Lonza Business Overview
- 12.11.3 Lonza Revenue in Microbiome CDMO Business (2021-2026)
- 12.11.4 Lonza Microbiome CDMO Product Portfolio
- 12.11.5 Lonza Recent Developments
- 12.12 MaaT Pharma
- 12.12.1 MaaT Pharma Company Information
- 12.12.2 MaaT Pharma Business Overview
- 12.12.3 MaaT Pharma Revenue in Microbiome CDMO Business (2021-2026)
- 12.12.4 MaaT Pharma Microbiome CDMO Product Portfolio
- 12.12.5 MaaT Pharma Recent Developments
- 12.13 NIZO
- 12.13.1 NIZO Company Information
- 12.13.2 NIZO Business Overview
- 12.13.3 NIZO Revenue in Microbiome CDMO Business (2021-2026)
- 12.13.4 NIZO Microbiome CDMO Product Portfolio
- 12.13.5 NIZO Recent Developments
- 12.14 Quay Pharmaceuticals
- 12.14.1 Quay Pharmaceuticals Company Information
- 12.14.2 Quay Pharmaceuticals Business Overview
- 12.14.3 Quay Pharmaceuticals Revenue in Microbiome CDMO Business (2021-2026)
- 12.14.4 Quay Pharmaceuticals Microbiome CDMO Product Portfolio
- 12.14.5 Quay Pharmaceuticals Recent Developments
- 12.15 Recipharm
- 12.15.1 Recipharm Company Information
- 12.15.2 Recipharm Business Overview
- 12.15.3 Recipharm Revenue in Microbiome CDMO Business (2021-2026)
- 12.15.4 Recipharm Microbiome CDMO Product Portfolio
- 12.15.5 Recipharm Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst